CONNEXIUS
Vaccines Asia
Conference 2027

CONFERENCE BROCHURE



CONNEXIUS VACCINES ASIA 2027

DATES

23–24 June 2027

LOCATION

Bangkok, Thailand

CONTENTS

01	Vaccines Asia Overview	03
02	Event at a Glance	04
03	Who Will You Meet	05
04	2027 Sponsors & Media Partners	06
05	2027 Speakers	07
06	Programme · Day 1	08
07	Programme · Day 2	10
08	Who Should Sponsor	12
09	Registration	13
10	Calendar of Events	14

01 · OVERVIEW

VACCINES ASIA OVERVIEW

Southeast Asia is making vaccine security a regional priority, and Thailand is at the heart of it.

673M
people across ASEAN's 10 member states, still largely reliant on imported vaccines

30.9×
return on a regional vaccine-security approach, vs 9.5× for countries acting alone

US$2.7B
regional investment needed in vaccine R&D, manufacturing and regulation, 2022–2040

11 of 12
national immunisation vaccines now made locally in Vietnam

Thailand at the centre

The National Vaccine Institute leads Thailand's 2023–2027 National Policy and Strategic Plan for Vaccine Security, spanning R&D, quality, production, procurement and immunisation. The Government Pharmaceutical Organization runs an award-winning influenza vaccine plant in Saraburi and is adopting SK bioscience's cell-culture flu technology, while KMUTT's National Biopharmaceutical Facility adds more than US$80 million of process development, characterisation and GMP capacity.

A region building capacity

Indonesia's Bio Farma produces over 3 billion doses a year, and Sanofi's modular plant in Singapore can make up to four vaccines at once. As ASEAN shapes the next phase of its Vaccine Security and Self-Reliance (AVSSR) agenda, the priorities are pooled demand, regulatory reliance and manufacturing spread across more countries, so the region can respond quickly when the next outbreak comes.

REGIONAL CAPABILITY IN FOCUS

THAILAND
GPO & SK bioscience
Cell-culture influenza vaccine technology transfer (MoU 2023)

THAILAND
KMUTT NBF
US$80M+ hub for process development, characterisation and GMP

SINGAPORE
Sanofi
US$595M modular plant that switches vaccines within days

INDONESIA
Bio Farma
3B+ doses a year and a WHO-prequalified exporter

Connexius Vaccines Asia 2027 follows the full vaccine journey, from discovery to supply and access, bringing together the developers, manufacturers, regulators and technology providers building this capability across Thailand and ASEAN.

Sources: World Bank, Investing in Vaccine Security in the ASEAN Region (2024); National Vaccine Institute, Thailand; ISPE; KMUTT National Biopharmaceutical Facility; Bio Farma; Sanofi; SK bioscience; Vietnam.vn; CEPI Regional Vaccine Manufacturing Collaborative (2026).

THE VACCINE JOURNEY

Discovery · Preclinical · Clinical · Process Development · Manufacturing · Fill-Finish · Quality · Regulatory · Supply & Access

CONNEXIUS Vaccines Asia Conference 2027

DATES
23–24 June 2027

LOCATION
Bangkok, Thailand

FORMAT
Conference & exhibition

Two days. The full vaccine journey. One room in Bangkok.

On 23–24 June 2027, Connexius Vaccines Asia brings the region's vaccine community together to explore the innovations and strategies advancing vaccine development, manufacturing and security across Thailand and ASEAN, with selected international participation.

EVENT AT A GLANCE

2	300–400	40–50	8	30–40
Days	**Attendees**	**Speakers**	**Core themes**	**Sponsors**
Insights & networking	Industry professionals	Industry experts	R&D, manufacturing & supply	Exhibitors & solution providers

WHAT'S ON THE PROGRAMME

DAY 1 — Wednesday, 23 June 2027

- I Next-Generation Vaccine Innovation
- II Preclinical & Clinical Development
- III Vaccine Platforms & Formulation
- IV Analytical Development, CMC & Regulatory

DAY 2 — Thursday, 24 June 2027

- V Process Development & Scale-Up
- VI Upstream & Downstream Processing
- VII The Next-Generation Vaccine Factory
- VIII Commercialisation, Supply & Security

WHY ATTEND

01 Gain insight
Technologies and strategies shaping the next phase of vaccine development and manufacturing.

02 Learn from experts
Technical and manufacturing leaders across the value chain, from R&D to supply.

03 Build partnerships
Peers, solution providers and partners from Thailand, ASEAN and across Asia.

04 Discover solutions
Technologies supporting flexibility, resilience and vaccine security across the region.

03 · AUDIENCE

WHO WILL YOU MEET

A senior, technical audience drawn from across the vaccine value chain, with 65% of delegates from Southeast Asia.


350	target delegates	**50%**	from vaccine biopharma & big pharma	**65%**	from Thailand, Singapore, Malaysia, Indonesia & Vietnam

BY JOB FUNCTION




Vaccine R&D / Discovery / Preclinical	20%
Process Development, Bioprocessing & MSAT	20%
Clinical Development & Medical Affairs	15%
Business Development / Partnerships	15%
CMC & Analytical Development	8%
Government, Public Health & Policy	8%
Quality & Regulatory Affairs	7%
Supply Chain, Procurement & Tech Transfer	7%

BY COMPANY PROFILE



Vaccine Biopharma & Big Pharma	50%
Solution & Service Providers	30%
Government, Regulators, Academia & Associations	15%
Other Industry Stakeholders	5%

BY COUNTRY



Thailand, Singapore, Malaysia, Indonesia & Vietnam	65%
South Korea, Japan, China & Taiwan	20%
Other Asia / International	10%
India	5%

Audience profile based on a target attendance of 350 delegates.

04 · PARTNERS

2027 SPONSORS & MEDIA PARTNERS

MEDIA PARTNERS

World Pharma Today

Life Sciences Review

MedTech Outlook

Bio Partner

Pharma Now

BioPharma Asia

2027 SPONSORS

PLATINUM SPONSOR
To be announced

GOLD SPONSORS
To be announced

SILVER SPONSORS
To be announced

EXHIBITORS
To be announced

Become a sponsor

Put your brand in front of 350 vaccine developers, manufacturers, regulators and technology buyers. Sponsorship, speaking, exhibition and roundtable packages are available.

connexiusgroup.com

2027 SPEAKERS



Associate Professor Pham Van Hung

Chairman
VABIOTECH
VIETNAM



Waranyoo Phoolcharoen, Ph.D.

Chief Technical Officer and Co-Founder
Baiya Phytopharm
THAILAND



Eriya Utaman, M.Sc

Vaccine Process Development Specialist
PT Bio Farma
INDONESIA



Vanessa Gomez

Head of Vaccines
Sanofi
PHILIPPINES



Dea Marsendah

Department Head of Bulk Conjugate Production
PT Bio Farma
INDONESIA

CONFERENCE PROGRAMME

DAY 1 · MORNING

Wednesday, 23 June 2027

Bangkok, Thailand

08:00 Registration, Morning Coffee & Exhibition

09:00 Chairperson's Welcome & Opening Remarks

SESSION I — NEXT-GENERATION VACCINE INNOVATION

09:10 — OPENING KEYNOTE

Building Asia's Next Generation Vaccine Ecosystem: From Innovation to Vaccine Security

- Strengthening regional capabilities across vaccine R&D, manufacturing and supply.
- Building sustainable public-private partnerships to accelerate vaccine development.
- Creating greater vaccine preparedness and manufacturing resilience across Asia.

09:30 — TECHNOLOGY SPOTLIGHT

AI & Computational Technologies in Next-Generation Vaccine Discovery

- Applying AI to antigen identification and vaccine candidate optimisation.
- Using predictive modelling to accelerate development decisions.
- Integrating computational tools with experimental vaccine R&D.

09:50 — INDUSTRY KEYNOTE

What's Next for Vaccines? Emerging Technologies Transforming Vaccine Development

- Evaluating next-generation platforms including mRNA, recombinant proteins and viral vectors.
- Improving speed, scalability and flexibility of vaccine development.
- Translating platform technologies from pandemic response into routine and emerging-disease vaccines.

10:10 Expert Exchange & Audience Q&A

10:25 Morning Networking Break & Exhibition Viewing

SESSION II — PRECLINICAL & CLINICAL DEVELOPMENT

11:10

Improving Translation from Preclinical Vaccine Development to First-in-Human Studies

- Selecting appropriate preclinical models and translational endpoints.
- Building stronger relationships between immunogenicity, safety and clinical outcomes.
- Identifying development risks earlier to improve candidate selection.

11:30

Accelerating Vaccine Development from Preclinical to Clinical Proof-of-Concept

- Integrating preclinical, bioanalytical and clinical capabilities to shorten timelines and enable faster decisions.
- Designing smarter development strategies to improve candidate selection, study design and translation to first-in-human.
- Leveraging advanced technologies, data and regional clinical capabilities while maintaining quality and regulatory readiness.

11:50

Accelerating Vaccine Clinical Development Across Asia

- Designing efficient clinical development strategies for diverse Asian populations.
- Improving site selection, recruitment and trial execution.
- Leveraging regional clinical networks to accelerate vaccine development.

12:10 Expert Exchange & Audience Q&A

12:25 Networking Lunch & Exhibition Viewing

CONFERENCE PROGRAMME

DAY 1 · AFTERNOON

Wednesday, 23 June 2027

Bangkok, Thailand

SESSION III — VACCINE PLATFORMS & FORMULATION

13:40

Beyond COVID-19: Unlocking the Next Generation of mRNA Vaccines

- Improving mRNA stability, expression and immune response.
- Advancing lipid nanoparticle and next-generation delivery technologies.
- Addressing manufacturing, scalability and storage challenges for broader vaccine applications.

14:00

The Next Generation of Vaccine Adjuvants: Improving Potency, Durability & Immune Response

- Selecting adjuvants for different vaccine platforms and target populations.
- Understanding the relationship between formulation and immune response.
- Overcoming development and manufacturing challenges associated with novel adjuvants.

14:20

Advancing Recombinant Protein & Subunit Vaccines for Future Disease Prevention

- Optimising antigen expression and recombinant protein production.
- Selecting platforms for scalability and cost-effective manufacturing.
- Improving immunogenicity through antigen engineering and formulation.

14:40 Expert Exchange & Audience Q&A

14:55 Afternoon Networking Coffee & Exhibition Viewing

SESSION IV — ANALYTICAL DEVELOPMENT, CMC & REGULATORY

15:40

From Candidate to Commercialisation: Building an Effective Vaccine CMC Strategy

- Integrating process, analytical and formulation development early in the vaccine lifecycle.
- Preparing CMC packages to support clinical progression and regulatory submissions.
- Managing process changes, comparability and scale-up as programmes mature.

16:00

Accelerating Vaccine Development Through Advanced Analytical Characterisation & Process Understanding

- Leveraging advanced analytics to strengthen identity, purity, potency and product-quality assessment.
- Building deeper process and product understanding to support comparability and scale-up.
- Developing robust, data-driven analytical strategies to support submissions while reducing timelines and risk.

16:20

Building a Robust Analytical Strategy for Vaccine Development

- Developing fit-for-purpose assays across the vaccine development lifecycle.
- Establishing potency, identity, purity and safety testing strategies.
- Supporting comparability and process changes through robust analytical characterisation.

16:40 Expert Exchange & Audience Q&A

16:55 Chairperson's Closing Remarks — Day 1



17:00 · DAY 1 EVENING

Networking Reception

Unwind after Day 1 as the sun sets over Bangkok, and continue the conversation with speakers, delegates, sponsors and media partners.

CONFERENCE PROGRAMME

DAY 2 · MORNING

Thursday, 24 June 2027

Bangkok, Thailand

SESSION V — PROCESS DEVELOPMENT & SCALE-UP

09:10

Building Flexible Vaccine Manufacturing for the Next Generation of Vaccines

- Designing facilities capable of supporting multiple vaccine platforms.
- Balancing manufacturing flexibility, capacity and cost.
- Building scalable manufacturing capabilities for routine and outbreak-response vaccines.

09:30

From Laboratory to Manufacturing: Overcoming Vaccine Scale-Up Challenges

- Translating laboratory processes into robust commercial manufacturing processes.
- Identifying critical process parameters during scale-up.
- Reducing technology-transfer and manufacturing risks through early process understanding.

09:50

Getting Tech Transfer Right: Moving Vaccine Processes Across Sites & Partners

- Establishing knowledge and process transfer between R&D, manufacturing sites, external partners and CDMOs.
- Managing comparability, equipment differences and site-specific requirements during transfer.
- Building cross-functional governance and documentation to reduce timelines, deviations and risk.

10:10 Expert Exchange & Audience Q&A

10:25 Morning Networking Break & Exhibition Viewing

SESSION VI — UPSTREAM & DOWNSTREAM PROCESSING

11:10

Optimising Upstream Processing for Higher Vaccine Productivity

- Optimising cell culture, fermentation and expression systems to increase yield and consistency.
- Improving media, feeding strategies and process parameters without compromising product quality.
- Applying enhanced monitoring and control to build robust, scalable upstream processes.

11:30

Designing Efficient Downstream Processes for Complex Vaccine Modalities

- Developing purification strategies for the complexity and diversity of modern vaccine platforms.
- Optimising chromatography, filtration and separation to improve recovery, purity and yield.
- Reducing downstream bottlenecks while balancing performance, scalability and cost of goods.

11:50

Building Flexible Vaccine Manufacturing Through Single-Use Technologies

- Evaluating where single-use systems offer greater flexibility, speed and operational efficiency.
- Designing scalable single-use strategies across upstream, downstream and supporting operations.
- Managing extractables and leachables, integrity, standardisation and supply-chain security.

12:10 Expert Exchange & Audience Q&A

12:25 Networking Lunch & Exhibition Viewing

CONFERENCE PROGRAMME

DAY 2 · AFTERNOON

Thursday, 24 June 2027

Bangkok, Thailand

SESSION VII — THE NEXT-GENERATION VACCINE FACTORY

13:40

Building the Digital Vaccine Factory: Automation, Data & AI in Manufacturing

- Connecting equipment, process and quality data for real-time visibility across operations.
- Applying AI, advanced analytics and predictive technologies to identify deviations earlier.
- Moving towards automated, paperless, data-driven manufacturing while maintaining GMP compliance and data integrity.

14:00

Scaling Vaccine Fill-Finish Without Compromising Quality

- Increasing fill-finish capacity while maintaining sterility, product integrity and consistent performance.
- Evaluating vial, prefilled syringe and other presentation strategies for different products and markets.
- Improving filling, inspection and packaging through automation and advanced technologies.

14:20

Quality by Design: Building Robust Vaccine Manufacturing Processes

- Defining CQAs and CPPs early to build quality into development and manufacturing.
- Applying process understanding, risk assessment and data to reduce variability.
- Using QbD to support scale-up, technology transfer, lifecycle management and regulatory readiness.

14:40 Expert Exchange & Audience Q&A

14:55 Afternoon Networking Coffee & Exhibition Viewing

SESSION VIII — VACCINE COMMERCIALISATION, SUPPLY & SECURITY

15:40

From Factory to Patient: Building Resilient Vaccine Supply & Cold-Chain Networks

- Strengthening temperature-controlled storage and distribution from facilities to vaccination points.
- Improving end-to-end visibility through real-time monitoring, track-and-trace and digital supply-chain tools.
- Building supply networks able to respond to demand fluctuations, disruptions and public-health emergencies.

16:00

Building Sustainable Vaccine Manufacturing Capacity Across ASEAN

- Identifying the capabilities ASEAN needs to strengthen regional manufacturing and supply resilience.
- Building capacity through technology transfer, public-private partnerships and regional collaboration.
- Balancing national vaccine-security objectives with commercial sustainability, utilisation and long-term demand.

16:20 — CLOSING PANEL

Vaccine Manufacturing 2030: Strengthening Asia's Vaccine Security & Preparedness

- Preparing manufacturing networks to respond rapidly to future pandemics, emerging infectious diseases and changing demand.
- Strengthening regional collaboration across R&D, manufacturing, regulation, procurement and supply.
- Defining the investments, partnerships and technologies needed for Asia to become a more self-reliant, globally competitive vaccine hub.

16:40 Expert Exchange & Audience Q&A

16:55 Chairperson's Closing Remarks & End of Conference

08 · SPONSORSHIP

WHO SHOULD SPONSOR

Every step of the vaccine journey maps to a supplier category on the programme.

01 Bioprocessing

SESSION VI

- Bioreactors & single-use systems
- Cell culture & media
- Filtration & chromatography
- Purification

02 Manufacturing

SESSIONS V · VII

- Processing equipment
- Automation
- Cleanrooms
- Facility engineering

03 Fill-finish

SESSION VII

- Filling equipment
- Vials, syringes & stoppers
- Inspection
- Packaging

04 Analytical & quality

SESSION IV

- Characterisation & QC
- PAT & instruments
- Testing services

05 Digital, automation & AI

SESSION VII

- MES & LIMS
- AI & data management
- Digital manufacturing

06 CDMOs & CROs

SESSIONS II · V

- Vaccine & process development
- Analytical & clinical services
- Manufacturing & fill-finish

07 Cold chain & logistics

SESSION VIII

- Storage & logistics
- Temperature monitoring
- Cold-chain packaging

Also a fit

- Clinical research & testing services
- Specialist process materials & services
- Quality & data software
- Facility design & engineering

SPEAK WITH OUR SPONSORSHIP TEAM

Roshinee Singh
Head of Business Development
roshinee.singh@connexiusgroup.com

Jack Baclaan
Business Development Manager
jack.baclaan@connexiusgroup.com

Jumarie Albit
Business Development Manager
jumarie.albit@connexiusgroup.com

09 · REGISTRATION

DELEGATE REGISTRATION

Connexius Vaccines Asia 2027 · 23–24 June 2027 · Bangkok. Register early for the best rate.

BEST RATE

DELEGATE CATEGORY	SUPER EARLY BIRD Valid until 28 February 2027	EARLY BIRD Valid until 30 April 2027	STANDARD RATE
Vaccine Biopharma, Big Pharma, Academics, Research Institutes & Government	SGD ***699***	SGD **899**	SGD **1,099**
Service & Solution Provider	SGD ***2,049***	SGD **2,249**	SGD **2,449**

All rates are per delegate in Singapore dollars (SGD).

CONFERENCE VENUE



VENUE

To be updated

ADDRESS

To be updated

DATES

23–24 June 2027

Secure your place Super Early Bird rates end 28 February 2027. **connexiusgroup.com**

CALENDAR OF EVENTS

Biopharma Pharma Healthcare

2027

MONTH	EVENT	DATES	LOCATION
May	Bioprocessing South Korea 2027	26–27 May 2027	Seoul, South Korea
June	Vaccines Asia Conference 2027	23–24 June 2027	Bangkok, Thailand
August	Smart Hospital Automation Asia 2027	3–4 August 2027	Bangkok, Thailand
September	Genome Editing Asia 2027	14–15 September 2027	Singapore
October	Sterile Manufacturing & Fill-Finish Asia 2027	12–13 October 2027	Singapore
October	Biologics SEA 2027	20–21 October 2027	Ho Chi Minh City, Vietnam

2028

		ES	LOCATION
April	Radiopharma & Theranostics Asia Congress 2028	18–19 April 2028	South Korea
May	Single-Use Bioprocessing APAC 2028	16–17 May 2028	Singapore
May	Asia Biopharma Manufacturing 2028	16–17 May 2028	Singapore
May	ADC Development & Manufacturing Asia 2028	24–25 May 2028	Seoul, South Korea
May	Bioprocessing South Korea 2028	24–25 May 2028	Seoul, South Korea
June	Healthcare Transformation Indonesia 2028	20–21 June 2028	Jakarta, Indonesia
July	API & Process Chemistry Asia	18–19 July 2028	Singapore
July	Pharma Process & Manufacturing Singapore	18–19 July 2028	Singapore
August	ANZBIO 2028	29–30 August 2028	Melbourne, Australia
August	APAC Clinical Trials 2028	29–30 August 2028	Melbourne, Australia
October	Surgical Innovations & Robotics Asia	17–18 October 2028	Singapore
October	Medical Imaging & AI Asia	17–18 October 2028	Singapore
October	Biologics SEA 2028	24–25 October 2028	Ho Chi Minh City, Vietnam